Cannabis Edibles for Dysmenorrhea

Dysmenorrhea is the word a clinician writes down for period pain, and getting the word changes the question. Between 16% and 91% of women of reproductive age have it, with severe pain in 2% to 29%, the range Ju and colleagues reached by pooling fifteen population studies in 2014. The label splits the reader in two: primary dysmenorrhea, a prostaglandin problem with no disease behind it, and secondary dysmenorrhea, a disease with period pain as its symptom. This page is for the first reader.

For primary dysmenorrhea an edible is second line. The drug class that blocks prostaglandin synthesis has the strongest evidence of anything on this page, and a cannabinoid does not do what ibuprofen does. An edible is for the reader whose NSAID does not do enough, who cannot take one, or who wants the worst day to have a floor under it. Taken at the first sign of cramping it holds six to eight hours. Taken once you are already curled up, it is late.

Is dysmenorrhea the same thing as menstrual cramps?

Same pain, clinical word. Primary dysmenorrhea is period pain with no disease behind it, driven by prostaglandins. Secondary dysmenorrhea is period pain caused by endometriosis, adenomyosis, or fibroids, and that reader belongs on our endometriosis page. The word changes the question from whether a gummy helps to what the diagnosis rules out.

Our menstrual cramps page answers the colloquial question, does an edible help my cramps. This page answers the clinical one, what the diagnosis changes. Primary dysmenorrhea usually starts within a year or two of the first period and follows a stable pattern. If the pain arrived later, has worsened over years, or outlasts the bleeding, the endometriosis pain page is the right one, and nothing below should delay that diagnosis.

Why are NSAIDs first line, and what do cannabinoids do instead?

Because NSAIDs block the enzyme that makes the prostaglandins, and the trials say so. The 2015 Cochrane review by Marjoribanks and colleagues pooled 80 randomized trials in 5,820 women and put NSAIDs at 4.37 times the odds of pain relief versus placebo. Cannabinoids do something else, on thinner evidence: THC relaxes uterine muscle and changes how pain is perceived.

If 18% of women on placebo get moderate or excellent relief, between 45% and 53% on an NSAID do. The review rated the evidence low quality, noted that 59% of the trials were commercially funded, and still called NSAIDs a very effective treatment. The cost is side effects at 1.29 times the odds of placebo, gastrointestinal ones in particular.

What THC does is mechanically different. In 2004 Dennedy and colleagues in Galway took strips of human uterine muscle at elective cesarean delivery, pregnant tissue, six specimens, and showed that anandamide and THC both relaxed the muscle directly, an effect a CB1 antagonist blocked and a CB2 antagonist did not. That is the whole of the human tissue evidence: a pregnant uterus in a dish, not a menstruating one in a person. THC also dampens pain perception centrally. Neither action touches prostaglandin synthesis. A gummy is not a plant-based ibuprofen.

Do THC edibles help primary dysmenorrhea?

Nobody has run a trial of a THC edible in primary dysmenorrhea. THC relaxes human uterine muscle through the CB1 receptor in a dish, and women with dysmenorrhea who use cannabis report that it helps. Those two facts sit a long way apart, and an edible works as a floor under the worst day rather than a rescue dose.

In the only qualitative study of primary dysmenorrhea patients and cannabis, Sinclair and colleagues ran virtual focus groups with 26 Australian women in 2022, and dissatisfaction with over-the-counter analgesics was the key driver. Barriers named: prescriber access, practitioner bias, cost, geography, drug-driving laws. That is this page's reader: the ibuprofen did not do enough, and she has already noticed.

The most useful edibles data comes from an endometriosis population, labeled as such. Sinclair's 2021 analysis of Strainprint app records covered 252 users with self-reported endometriosis logging 16,193 cannabis sessions. Two thirds of sessions were inhaled, pain was the target in 57%, and inhaled forms scored higher for pain while oral forms did better on mood and gastrointestinal symptoms. The authors read the inhalation preference as an onset story: smoke works in minutes, a gummy in an hour or two. So an edible is not the thing you take when the cramp hits. It is the thing you take before it does, to put a six-to-eight-hour floor under the worst day and the night after it. Seifalian's 2022 review and the same group's 2023 review in Drugs land in the same place: no randomized trial of an oral product yet.

Is CBD alone enough for period pain?

Not at gummy doses. The only oral CBD trial in menstrual symptoms used 320 or 640 mg a day, open-label, in 33 women, with no placebo arm. A hemp period gummy carries 10 to 25 mg. The suppository study that gets quoted used 100 mg vaginally and was funded by the company that sells it.

The CBD evidence does not take long. Ferretti and colleagues in 2024 randomized 33 women to CBD isolate softgels at 160 mg twice a day (17 women) or 320 mg twice a day (16 women), five consecutive days a month for three cycles after a one-month baseline. Both groups reported lower menstrual symptom, irritability, anxiety, and stress scores than at baseline, depression did not move, and the outcome was menstrual symptoms as a bundle rather than pain alone. No placebo, and two of the five authors list Canopy Growth and Charlotte's Web as affiliations. Dahlgren and colleagues the same year compared 77 women using a 100 mg hemp-derived CBD vaginal suppository against 230 on treatment as usual and found lower symptom frequency and severity over two cycles. The acknowledgements say funding came from Foria, which makes the suppository. There is also a tampon. A head-to-head trial of oral CBD against ibuprofen was designed and, as of this writing, has not reported.

Now the shelf. Hemp brands sell "period gummies" and "PMS gummies" at 10 to 25 mg of CBD and zero THC for $30 to $40 a bag. The lowest dose anyone has tested by mouth for menstrual symptoms is 320 mg a day. A 25 mg gummy is about a thirteenth of that, a 10 mg gummy about a thirty-second, and the same brand often sells the identical gummy for sleep with a moon on the bag instead of a uterus. Those products are hemp-derived, and the federal redefinition tracked on our hemp ban page reaches them in two stages, with cannabinoids the plant cannot naturally produce losing hemp status on November 12, 2026 and the rest of the new definition taking effect December 11. In a 1:1 or 2:1 gummy the THC is doing the work. The CBD is there for tolerability, and this page says so.

Should you take an edible or an NSAID for dysmenorrhea?

The NSAID first, if you can take one. Eighty randomized trials put NSAIDs at roughly four times the odds of meaningful relief versus placebo. An edible is for the reader whose NSAID does not do enough or who cannot take one, and both need the same timing: at the first sign, before the peak.

Prostaglandin release starts as the lining breaks down, so an NSAID taken at the first twinge gets ahead of the synthesis rather than chasing contractions already under way. An edible has the same rule and a worse onset, 60 to 120 minutes for a standard gummy, so the margin for lateness is smaller.

How much THC for dysmenorrhea, and in what ratio?

For a first cycle, 2.5 mg of THC with equal or double the CBD, taken at the first sign of cramping. Someone who knows her response can start at 5 mg. No second dose inside two hours. The one second dose this page endorses is at bedtime on the worst night, because that night is where the floor matters most.

THC is the active half at these doses, and 2.5 to 5 mg is the range where most people get an effect without impairment that stops them working. The CBD in a 1:1 or 2:1 product takes the edge off THC's anxious side and does little else at 5 or 10 mg. Our dosing guide covers the titration rules. Three products, pulled from their brand sources on September 22, 2026:

The Petra mint is the first-cycle product: 2.5 mg of each cannabinoid, xylitol instead of sugar, forty to a tin, and a dose ceiling built into the format. The Papa & Barkley gummy is the 5 mg pick for the reader who knows her response, a 1:1 THC to CBD core with 5 mg of CBG riding along, about a dollar a piece on Los Angeles menus. It leads our pain gummy ranking.

The Wana gummy is the one to argue with. Its 5 to 15 minute onset is the right specification for a cramp already building. Three problems. No CBD, so the tolerability pairing has to come from somewhere else. At about $30 for 50 mg of THC it costs roughly 60 cents a milligram against the Papa & Barkley gummy's 20 or so. And Wana's own page lists a 2 to 4 hour duration for its fast-acting line against 6 hours for a standard gummy, backwards for the floor this page recommends. Fast onset buys speed and spends duration. For dysmenorrhea it is the second product to buy.

When should period pain be checked for something else?

When it does not behave like primary dysmenorrhea. Pain that starts before bleeding and outlasts it, pain that has worsened over years, pain with sex or bowel movements, or pain that does not respond to an NSAID plus hormonal contraception is a reason to be evaluated for endometriosis, adenomyosis, or fibroids rather than a reason to raise the dose.

The American College of Obstetricians and Gynecologists put the rule in writing in Committee Opinion 760: when a patient does not improve within three to six months of starting therapy, her obstetrician-gynecologist should investigate for possible secondary causes, and endometriosis should be considered in persistent, clinically significant dysmenorrhea despite treatment with hormonal agents and NSAIDs. The opinion is written about adolescents, and the logic transfers to adults unchanged. A product that blunts the pain of an undiagnosed secondary cause makes the pain look managed while the cause goes on, and the endometriosis pain page is where that reader belongs. This page closes the Women's Health cluster, where every page makes the same trade: the product is the smaller decision.

One last thing the diagnosis buys you. Primary dysmenorrhea improves with age, childbearing, and oral contraceptives, and Ju's review found family history the strongest risk factor, with odds ratios between 3.8 and 20.7. A woman told her pain is primary has been told it has a shape, a trajectory, and a first-line drug with 80 trials behind it. The gummy is what you add on the day that drug falls short. It was never the plan.